Stay updated with breaking news from Nasdaq Nrix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on […]
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) CFO Houte Hans Van sold 10,906 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $10.00, for a total value of $109,060.00. Following the sale, the chief financial officer now owns 75,471 shares […]
-logo.png?v=20230214135653&w=240&h=240&zc=2){kind=logo}
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and Hansa Biopharma AB (publ) (OTCMKTS:HNSBF – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability. Valuation and Earnings This table compares […]
Needham & Company LLC reaffirmed their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. Needham & Company LLC currently has a $31.00 price objective on the stock. Separately, HC Wainwright raised their price target on Nurix Therapeutics from $33.00 to […]
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.16, MarketWatch Earnings reports. The firm had revenue of $18.47 million for the quarter, compared to the consensus estimate of $19.98 million. Nurix […]